FDA Cites Boston Scientific For GMP Violations In Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific plans to meet with FDA the week of June 6 to discuss corrective measures to fix "serious regulatory problems" with the firm's Vaxcel low profile infusion ports